EXETER, N.H., Sept. 19 /PRNewswire-FirstCall/ -- Bentley Pharmaceuticals, Inc. (NYSE: BNT - News), a specialty pharmaceutical company, announced today that it has secured capacity at Cardinal Health’s (NYSE: CAH - News) new North Raleigh facility for the scale-up and manufacture of clinical supplies of Bentley’s intranasal insulin product candidate, facilitating the expansion of clinical trials.
